Loading people...
Greg Verdine is a Venture Partner at 6 Dimensions Capital and the Co-founder and CEO of both FogPharma and LifeMine Therapeutics, based in the Greater Boston Area. Before transitioning to full-time entrepreneurship, he spent over three decades as the Erving Professor of Chemistry at Harvard University, following a Ph.D. from Columbia University and postdoctoral research at MIT. He has founded or co-founded more than ten biotechnology companies, including Adnexus, which was acquired by Bristol-Myers Squibb, and previously held venture roles at Third Rock Ventures. Under his leadership, his current ventures have secured significant capital, with LifeMine Therapeutics raising a $175 million Series C in 2022 and FogPharma closing a $145 million Series E financing round in March 2024. His current focus remains on bridging academic chemical biology with commercial drug discovery to develop novel therapeutics.
Greg Verdine stands as a towering figure in the biotechnology and life sciences investment landscape, serving as a distinguished Venture Partner at 6 Dimensions Capital. In this pivotal role, he brings an unparalleled depth of scientific expertise, entrepreneurial acumen, and strategic vision to the firm's investment decisions. 6 Dimensions Capital, a leading healthcare-focused venture capital firm, benefits immensely from Verdine's insights, particularly in identifying and nurturing groundbreaking innovations in biopharmaceuticals, medical technology, and digital health.
Verdine's investment focus at 6 Dimensions Capital is sharply honed on the cutting edge of scientific discovery. He is particularly interested in companies developing novel therapeutic modalities, pioneering new approaches to drug discovery, and addressing previously "undruggable" targets. His expertise spans a wide array of areas within life sciences, including small molecule therapeutics, protein degradation, and other innovative platforms designed to tackle complex diseases. He seeks out ventures that possess robust scientific foundations, strong intellectual property, and the potential to create transformative impact for patients.
Beyond his contributions to 6 Dimensions Capital, Greg Verdine's career background is a testament to his profound influence on modern biotechnology. He holds esteemed positions as a Professor at Harvard University, where his research continues to push the boundaries of chemical biology and drug discovery. Verdine is perhaps best known as a prolific serial entrepreneur, having founded numerous highly successful biotechnology companies. These include pioneering ventures such as VentureLabs, Warp Drive Bio, Eleven Biotherapeutics, Aileron Therapeutics, Gloucester Pharmaceuticals, Ontorii, LifeMine Therapeutics, and Foghorn Therapeutics, among others. Many of these companies have gone on to achieve significant milestones, including public offerings and strategic acquisitions, underscoring his ability to translate fundamental scientific breakthroughs into viable, high-growth commercial enterprises.
His unique blend of academic rigor, entrepreneurial drive, and venture capital experience positions him as a critical bridge between cutting-edge research and market-ready solutions. Verdine's work at 6 Dimensions Capital and throughout his career exemplifies a commitment to fostering innovation that not only generates financial returns but also significantly advances human health. He is a driving force in shaping the future of medicine, consistently identifying and supporting the next generation of biotech leaders and therapeutic breakthroughs.
Greg Verdine is a distinguished Venture Partner at 6 Dimensions Capital, a renowned Harvard University Professor, and a highly successful serial entrepreneur in the biotechnology sector. He is known for founding numerous innovative biotech companies and his expertise in drug discovery.
Greg Verdine invests in groundbreaking life science companies, with a particular focus on novel therapeutic modalities, drug discovery platforms, and innovative solutions in biopharmaceuticals. He seeks ventures with strong scientific foundations and the potential for transformative impact.
Greg Verdine works as a Venture Partner at 6 Dimensions Capital, a healthcare-focused venture capital firm. He also holds a professorship at Harvard University, contributing to research and education in chemical biology and drug discovery.
